TP Therapeutics Announces Phase 1 Data of Ropotrectinib (TPX-0005) to be Presented at the Annual American Society of Clinical Oncology Meeting

SAN DIEGO–(BUSINESS WIRE)–TP Therapeutics, Inc., a privately held, clinical-stage
biopharmaceutical company developing oncology therapies with a focus on
addressing current drug resistance, announced today that the Phase 1
data from the ongoing TRIDENT-1 Study of Ropotrectinib (TPX-0005) has
been accepted for poster presentation and discussion on June 4 at the
upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in
Chicago, Illinois.

The presentation is entitled “A phase 1 study of the next-generation
ALK/ROS1/TRK inhibitor Ropotrectinib (TPX-0005) in patients with
advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)”.

The schedule for the poster display and discussion is as follows:

Poster Discussion
Time: 6/4/2018, 3:00 PM-4:15 PM

Title: A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor
Ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+
cancers (TRIDENT-1)

Abstract Number: 2513
Session Title:
Developmental Therapeutics—Clinical Pharmacology and Experimental
Therapeutics
Location: S406
Discussant: Valentina Boni, MD,
PhD, START Madrid CIOCC Hospital Universitario Sanchinarro

Poster Display Information: Monday, June 4, 2018, 8:00-11:30 am
Location:
Hall A
Lead author: Alexander Drilon, MD, Memorial Sloan Kettering
Cancer Center

About Ropotrectinib (TPX-0005)

Ropotrectinib (TPX-0005) is a potent and orally bioavailable
investigational small molecule kinase inhibitor for ALK, ROS1, and TRK
family. The clinical benefits of targeting ALK, ROS1, or TRK fusion
kinase have been demonstrated with multiple kinase inhibitors already
approved for the treatment of ALK+ non-small cell lung cancer
(NSCLC), in addition to crizotinib for ROS1+ NSCLC, and
larotrectinib and entrectinib in clinical studies for TRK+
cancers. The successes of these therapies are overshadowed by the
development of acquired resistance. The acquired solvent front mutations
including ALK G1202R, ROS1 G2032R, TRKA G595R and TRKC G623R render a
common clinical resistance to the current ALK, ROS1, and TRK inhibitors.
TPX-0005 is a potent kinase inhibitor against wildtype and mutated ALK,
ROS1 and TRK family kinases, especially the clinically significant
solvent front mutations, gatekeeper mutations, and emerging compound
mutations after multiple line treatments. Ropotrectinib may provide new
opportunities in the clinic to inhibit the abnormal signaling of ALK,
ROS1, or TRK family in solid malignancies, and overcome resistance seen
in refractory patients. TPX-0005 is currently being evaluated in a Phase
1/2, open-label, multi-center, first-in-human study of the safety,
tolerability, pharmacokinetics and anti-tumor activity in patients with
advanced solid tumors harboring ALK, ROS1, or NTRK1-3
rearrangements (TRIDENT-1, NCT03093116).
For additional information about ropotrectinib trial, please refer to www.clinicaltrials.gov.
Interested patients and physicians can also contact the TP Therapeutics
Oncology Clinical Trial Hotline at 1-858-276-0005 or email clinical@tptherapeutics.com.

About TP Therapeutics, Inc.

TP Therapeutics, Inc. (TP) is a clinical-stage structure-based oncology
drug design company founded in October 2013 by Dr. J. Jean Cui, the lead
inventor of Pfizer’s oncology drugs crizotinib and lorlatinib. The TP
team is focused on the design and development of novel chemical entities
within oncology for established oncogene drivers with high incidence of
secondary resistance mutations; newly identified disease-driven targets;
and potential targets regulating tumor microenvironment and tumor
immunity. For more information, please visit us at www.tptherapeutics.com.

Contacts

TP Therapeutics, Inc.
Y. Peter Li, Ph.D., M.B.A.
(858) 926-5251
peter.li@tptherapeutics.com